BPC 157 + TB 500

What it is

Two repair peptides in a single vial. They are studied for the same reason: helping the body repair damaged tissue —tendons, muscle, ligaments— faster than it would on its own.

BPC-157 is a laboratory copy of a small protein already present in human gastric juice. TB-500 is the active part of another protein, thymosin beta-4, which the body produces wherever there is a wound. Each one works in a different phase of repair, which is why they are combined.

What it is used for

• • Tendon, ligament and muscle injuries that are slow to heal
• • Recovery after intense exertion or surgery
• • Digestive discomfort: the original research field of BPC-157
• • Laboratory work on wound healing and new blood vessel formation

How it is used

The vial comes as a powder. It is reconstituted with bacteriostatic water, swirled gently until dissolved —never shaken— and kept in the refrigerator between 2 and 8 °C. Each vial contains 20 mg in total: 10 mg of each peptide.

What has been observed

Results described in the published scientific literature. They are not directions for use or health recommendations.

• • Preclinical studies describe faster healing of tendon, muscle, bone and intestine with BPC-157, including reattachment of tendon to bone after Achilles tendon detachment ^[2][3]
• • BPC-157 has shown activity at very small doses and without demonstrable toxicity in the models reviewed ^[2][5]
• • Thymosin beta-4 accelerates skin wound closure: in the original model, 42% more re-epithelialization at 4 days and up to 61% at 7 days ^[7]
• • It also reduces the number of myofibroblasts, which is associated with less scarring and less fibrosis ^[9]
• • Thymosin beta-4 reached human studies for skin wounds, corneal injuries and cardiac repair ^[9]
• • The published pilot studies in people with BPC-157 reported no relevant adverse effects ^[4]

How it works

BPC-157 — cytoprotection and angiogenesis

A stable pentadecapeptide derived from a gastric protein. In preclinical models it promotes angiogenesis, modulates the nitric oxide pathway and shows broad cytoprotective effects in gastrointestinal, musculoskeletal and nervous tissue ^[2]. In tendon it promotes fibroblast outgrowth from the explant, their survival under stress and their migration, an effect attributed to activation of the FAK-paxillin pathway ^[1].

TB-500 — cell migration and remodeling

The active fraction of thymosin beta-4, the main actin-sequestering molecule in eukaryotic cells. It regulates the actin cytoskeleton and directs the migration of repair cells toward the injury, in addition to modulating the inflammatory response ^[6][9]. Its own actin-binding site is responsible for promoting angiogenesis ^[8].

Why they are combined

They cover complementary phases of the same cascade: BPC-157 provides cytoprotection, trophic signaling and blood vessel formation; TB-500 provides cell migration and cytoskeletal remodeling. Together they span more stages of the repair process than either one alone.

State of the evidence

Preclinical: solid; clinical: limited. Reviews published in 2025 note that in humans there are only pilot studies with BPC-157 —intra-articular knee pain, interstitial cystitis and an intravenous safety and pharmacokinetics study— and that large, rigorous clinical trials are lacking; the long-term safety profile has not been established ^[4][5]. There are no published studies on the combined formulation: the available evidence is that of each component separately.

⚠️ Product intended exclusively for research and laboratory use. Not for human or veterinary consumption.

References

1. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol, 2011. PubMed 21030672
2. Gwyer D, et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res, 2019. PubMed 30915550
3. Krivic A, et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res, 2006. PubMed 16583442
4. Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J, 2025. PubMed 40756949
5. McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med, 2025. PubMed 40789979
6. Goldstein AL, et al. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med, 2005. PubMed 16099219
7. Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol, 1999. PubMed 10469335
8. Philp D, et al. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J, 2003. PubMed 14500546
9. Goldstein AL, et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther, 2012. PubMed 22074294